Introduction: Understanding the mechanism of DILI with MTA, and how to avoid and manage
these toxicities is essential for minimising inferior cancer treatment outcomes. An organised …

Introduction: The development of EGFR TKI and the subsequent identification of activating
EGFR mutations have dramatically changed how NSCLC is treated. With its recent approval …

Background Multikinase inhibitors (MKI) are targeted molecular agents that have
revolutionized cancer management. However, there is a paucity of data concerning MKI …

Purpose Hepatic injury is a common side effect following tyrosine kinase inhibitor (TKI)
therapy and our understanding usually comes from clinical trials. In this retrospective study …

表皮生长因子受体酪氨酸激酶抑制剂 (epidermal growth factor receptor-tyrosine kinase
inhibitors, EGFR-TKI) 如吉非替尼, 厄洛替尼, 埃克替尼和阿法替尼在中国已成为 EGFR …

目的： 药物治疗是肿瘤治疗的重要手段, 传统的化疗药物疗效欠佳、 副作用大,
因此以酪氨酸激酶抑制剂为代表的分子靶向抗肿瘤药物得到大力发展。 分子靶向抗肿瘤药物 …

Objective Drug therapy is essential for cancer treatment. The molecular targeted anticancer
drugs develop rapidly in recent years, since the effectiveness of traditional chemotherapy is …

ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib,
which are approved as a frontline treatment for patients with non-small cell lung cancer …